Zdrowie i gospodarka · 28/06/2021

FDA Publishes Draft Guidance on Sponsor Responsibilities for IND Safety Reporting and Bioavailability/Bioequivalence Studies

The FDA has released a draft guidance for industry outlining sponsor responsibilities for reporting safety data from investigational new drug applications and bioavailability/bioequivalence studies, replacing an earlier 2015 draft guidance